Vertex posts loss, raises cystic fibrosis sales view

Vertex posts loss, raises cystic fibrosis sales view
(Reuters) – Vertex Pharmaceuticals Inc on Tuesday increased by $20 million the 2013 forecast for sales of its cystic fibrosis drug that has become the focus for investors, and its shares rose 1 percent despite posting a first-quarter loss on plunging sales of its hepatitis C drug, Incivek.

Source

Comments are closed.